A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-03-10) →
What happened
Shinpoong Pharmaceutical reported consolidated results for FY2025: revenue of US$163M (+6.15% year on year), operating profit of US$9.88M (from a loss a year earlier) and net income of US$5.71M (from a loss a year earlier).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$163M |
|---|---|
| Revenue vs a year earlier | +6.15% |
| Operating profit | US$9.88M |
| Net income | US$5.71M |
| Period | FY2025 (consolidated) |
| Filed | 2026-02-23, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260223800379 → open original filing |
Versions of this filing
- 2026-02-23Original (this page)
- 2026-03-10Amendment 1
Source: DART. Information only, not investment advice.